A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

Alison T Stopeck, Joseph M. Unger, Lisa M Rimsza, William T. Bellamy, Maria E Iannone, Daniel Persky, Michael Leblanc, Richard Fisher, Thomas P Miller

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

This is the first report of the Southwest oncology group phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma (NHL). Fifty-two patients in first or second relapse with diffuse large B-cell or mantle cell lymphoma were enrolled. Patients were treated with bevacizumab at 10 mg/kg every 2 weeks. Therapy was well tolerated with no unexpected toxicities observed. Six-month progression-free survival (PFS) was 16% with a response rate of 2% and median duration of response or stable disease of 5.2 months (range 3.5-72.7). Vascular endothelial growth factor A (VEGF) and VEGF receptor expression was observed in 70% and 65% of specimens, respectively. In an exploratory subgroup analysis, baseline urine VEGF and plasma vascular cell adhesion molecule-1 (VCAM) levels correlated with survival. Prolonged PFS in several patients as well as biomarker studies suggest the VEGF pathway plays an important role in aggressive NHL. Clinical trials combining active chemotherapy regimens with VEGF targeted agents are currently in progress.

Original languageEnglish (US)
Pages (from-to)728-735
Number of pages8
JournalLeukemia and Lymphoma
Volume50
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Non-Hodgkin's Lymphoma
Vascular Endothelial Growth Factor A
Disease-Free Survival
Mantle-Cell Lymphoma
Vascular Endothelial Growth Factor Receptor
Vascular Cell Adhesion Molecule-1
Plasma Cells
B-Lymphocytes
Biomarkers
Bevacizumab
Clinical Trials
Urine
Recurrence
Drug Therapy
Survival
Therapeutics

Keywords

  • Bevacizumab
  • Clinical trial
  • Non-Hodgkin lymphoma
  • VEGF

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma : Southwest oncology group study S0108. / Stopeck, Alison T; Unger, Joseph M.; Rimsza, Lisa M; Bellamy, William T.; Iannone, Maria E; Persky, Daniel; Leblanc, Michael; Fisher, Richard; Miller, Thomas P.

In: Leukemia and Lymphoma, Vol. 50, No. 5, 2009, p. 728-735.

Research output: Contribution to journalArticle

@article{6b03b12d6f274cfda0bc9a84e7ec2dab,
title = "A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108",
abstract = "This is the first report of the Southwest oncology group phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma (NHL). Fifty-two patients in first or second relapse with diffuse large B-cell or mantle cell lymphoma were enrolled. Patients were treated with bevacizumab at 10 mg/kg every 2 weeks. Therapy was well tolerated with no unexpected toxicities observed. Six-month progression-free survival (PFS) was 16{\%} with a response rate of 2{\%} and median duration of response or stable disease of 5.2 months (range 3.5-72.7). Vascular endothelial growth factor A (VEGF) and VEGF receptor expression was observed in 70{\%} and 65{\%} of specimens, respectively. In an exploratory subgroup analysis, baseline urine VEGF and plasma vascular cell adhesion molecule-1 (VCAM) levels correlated with survival. Prolonged PFS in several patients as well as biomarker studies suggest the VEGF pathway plays an important role in aggressive NHL. Clinical trials combining active chemotherapy regimens with VEGF targeted agents are currently in progress.",
keywords = "Bevacizumab, Clinical trial, Non-Hodgkin lymphoma, VEGF",
author = "Stopeck, {Alison T} and Unger, {Joseph M.} and Rimsza, {Lisa M} and Bellamy, {William T.} and Iannone, {Maria E} and Daniel Persky and Michael Leblanc and Richard Fisher and Miller, {Thomas P}",
year = "2009",
doi = "10.1080/10428190902856808",
language = "English (US)",
volume = "50",
pages = "728--735",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma

T2 - Southwest oncology group study S0108

AU - Stopeck, Alison T

AU - Unger, Joseph M.

AU - Rimsza, Lisa M

AU - Bellamy, William T.

AU - Iannone, Maria E

AU - Persky, Daniel

AU - Leblanc, Michael

AU - Fisher, Richard

AU - Miller, Thomas P

PY - 2009

Y1 - 2009

N2 - This is the first report of the Southwest oncology group phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma (NHL). Fifty-two patients in first or second relapse with diffuse large B-cell or mantle cell lymphoma were enrolled. Patients were treated with bevacizumab at 10 mg/kg every 2 weeks. Therapy was well tolerated with no unexpected toxicities observed. Six-month progression-free survival (PFS) was 16% with a response rate of 2% and median duration of response or stable disease of 5.2 months (range 3.5-72.7). Vascular endothelial growth factor A (VEGF) and VEGF receptor expression was observed in 70% and 65% of specimens, respectively. In an exploratory subgroup analysis, baseline urine VEGF and plasma vascular cell adhesion molecule-1 (VCAM) levels correlated with survival. Prolonged PFS in several patients as well as biomarker studies suggest the VEGF pathway plays an important role in aggressive NHL. Clinical trials combining active chemotherapy regimens with VEGF targeted agents are currently in progress.

AB - This is the first report of the Southwest oncology group phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma (NHL). Fifty-two patients in first or second relapse with diffuse large B-cell or mantle cell lymphoma were enrolled. Patients were treated with bevacizumab at 10 mg/kg every 2 weeks. Therapy was well tolerated with no unexpected toxicities observed. Six-month progression-free survival (PFS) was 16% with a response rate of 2% and median duration of response or stable disease of 5.2 months (range 3.5-72.7). Vascular endothelial growth factor A (VEGF) and VEGF receptor expression was observed in 70% and 65% of specimens, respectively. In an exploratory subgroup analysis, baseline urine VEGF and plasma vascular cell adhesion molecule-1 (VCAM) levels correlated with survival. Prolonged PFS in several patients as well as biomarker studies suggest the VEGF pathway plays an important role in aggressive NHL. Clinical trials combining active chemotherapy regimens with VEGF targeted agents are currently in progress.

KW - Bevacizumab

KW - Clinical trial

KW - Non-Hodgkin lymphoma

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=67650866822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650866822&partnerID=8YFLogxK

U2 - 10.1080/10428190902856808

DO - 10.1080/10428190902856808

M3 - Article

C2 - 19373598

AN - SCOPUS:67650866822

VL - 50

SP - 728

EP - 735

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -